基于纵向数据与游离DNA特征的新型高精度肝细胞癌预测模型
研究基于中国61家中心13728例以慢性乙型肝炎为主的患者,开发并外部验证了aMAP-2和aMAP-2 Plus两个肝细胞癌预测模型。aMAP-2结合纵向aMAP与甲胎蛋白数据,AUC 0.83-0.84;aMAP-2 Plus加入游离DNA特征,在肝硬化患者中AUC 0.85-0.89。逐步应用aMAP评分可有效富集高危人群。
要点
- aMAP-2模型在训练与外部验证队列中AUC为0.83-0.84。
- aMAP-2将aMAP定义的高危患者5年累积肝细胞癌发生率分为23.4%与4.1%(p=0.0065)。
- aMAP-2 Plus在肝硬化患者中AUC为0.85-0.89,逐步策略将肝硬化患者年发生率分为0.8%与12.5%(p<0.0001)。
核心结论
- aMAP-2和aMAP-2 Plus评分在预测肝细胞癌方面具有高准确性。
- 逐步应用aMAP评分可改进富集策略,识别肝细胞癌高危患者,可能有效指导个体化肝细胞癌监测。
研究设计与样本
- 研究纳入来自两个全国性多中心前瞻性观察队列的13728例患者,多数患有慢性乙型肝炎。
- 研究基于中国大陆61家中心的13728例患者,开发并外部验证了两个新的肝细胞癌风险预测模型。
- 采用纵向判别分析算法对患者生物标志物的纵向特征建模,并估计肝细胞癌发生风险。
- 使用低覆盖度全基因组测序获取多模态游离DNA片段组学特征。
主要发现
- aMAP-2评分基于随访长达8年的纵向aMAP评分与甲胎蛋白值计算,在训练和外部验证队列中AUC为0.83-0.84。
- aMAP-2评分将aMAP定义的高危患者分为两组,5年累积肝细胞癌发生率分别为23.4%和4.1%(p=0.0065)。
- aMAP-2 Plus评分纳入游离DNA特征(核小体、片段和基序评分),优化了肝细胞癌发生预测,尤其在肝硬化患者中AUC为0.85-0.89。
- 逐步应用aMAP评分(aMAP→aMAP-2→aMAP-2 Plus)将肝硬化患者分为两组,分别占队列的90%和10%,年肝细胞癌发生率分别为0.8%和12.5%(p<0.0001)。
- aMAP-2和aMAP-2 Plus评分的性能在所有亚组中均明显优于原始aMAP评分及任何其他现有肝细胞癌风险评分,尤其在肝硬化患者中。
关键数值与推荐
- aMAP-2评分在训练和外部验证队列中AUC为0.83-0.84。
- aMAP-2评分将aMAP定义的高危患者5年累积肝细胞癌发生率分为23.4%与4.1%(p=0.0065)。
- aMAP-2 Plus评分在肝硬化患者中AUC为0.85-0.89。
- 逐步应用aMAP评分将肝硬化患者分为占队列90%和10%的两组,年肝细胞癌发生率分别为0.8%和12.5%(p<0.0001)。
临床怎么用
- 逐步应用aMAP评分(aMAP→aMAP-2→aMAP-2 Plus)提供改进的富集策略,识别肝细胞癌高危患者,可能有效指导个体化肝细胞癌监测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Current hepatocellular carcinoma (HCC) risk scores do not reflect changes in HCC risk resulting from liver disease progression/regression over time. We aimed to develop and validate two novel prediction models using multivariate longitudinal data, with or without cell-free DNA (cfDNA) signatures. METHODS: A total of 13,728 patients from two nationwide multicenter prospective observational cohorts, the majority of whom had chronic hepatitis B, were enrolled. aMAP score, as one of the most promising HCC prediction models, was evaluated for each patient. Low-pass whole-genome sequencing was used to derive multi-modal cfDNA fragmentomics features. A longitudinal discriminant analysis algorithm was used to model longitudinal profiles of patient biomarkers and estimate the risk of HCC development. RESULTS: We developed and externally validated two novel HCC prediction models with a greater accuracy, termed aMAP-2 and aMAP-2 Plus scores. The aMAP-2 score, calculated with longitudinal data on the aMAP score and alpha-fetoprotein values during an up to 8-year follow-up, performed superbly in the training and external validation cohorts (AUC 0.83-0.84). The aMAP-2 score showed further improvement and accurately divided aMAP-defined high-risk patients into two groups with 5-year cumulative HCC incidences of 23.4% and 4.1%, respectively (p = 0.0065). The aMAP-2 Plus score, which incorporates cfDNA signatures (nucleosome, fragment and motif scores), optimized the prediction of HCC development, especially for patients with cirrhosis (AUC 0.85-0.89). Importantly, the stepwise approach (aMAP -> aMAP-2 -> aMAP-2 Plus) stratified patients with cirrhosis into two groups, comprising 90% and 10% of the cohort, with an annual HCC incidence of 0.8% and 12.5%, respectively (p <0.0001). CONCLUSIONS: aMAP-2 and aMAP-2 Plus scores are highly accurate in predicting HCC. The stepwise application of aMAP scores provides an improved enrichment strategy, identifying patients at a high risk of HCC, which could effectively guide individualized HCC surveillance. IMPACT AND IMPLICATIONS: In this multicenter nationwide cohort study, we developed and externally validated two novel hepatocellular carcinoma (HCC) risk prediction models (called aMAP-2 and aMAP-2 Plus scores), using longitudinal discriminant analysis algorithm and longitudinal data (i.e., aMAP and alpha-fetoprotein) with or without the addition of cell-free DNA signatures, based on 13,728 patients from 61 centers across mainland China. Our findings demonstrated that the performance of aMAP-2 and aMAP-2 Plus scores was markedly better than the original aMAP score, and any other existing HCC risk scores across all subsets, especially for patients with cirrhosis. More importantly, the stepwise application of aMAP scores (aMAP -> aMAP-2 -> aMAP-2 Plus) provides an improved enrichment strategy, identifying patients at high risk of HCC, which could effectively guide individualized HCC surveillance.
引用
- Fan R, Chen L, Zhao S, et al. Novel, high accuracy models for hepatocellular carcinoma prediction based on longitudinal data and cell-free DNA signatures. J Hepatol. 2023. PMID: 37302583. doi:10.1016/j.jhep.2023.05.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。